Product Overview

IR2Dx partners with CLIA laboratories and health systems to provide customized reports with proprietary analyses of diagnostic test results. These test results are designed to measure the underlying, disease driving pathways involved in metabolic regulation. Each analysis is interpreted using the clinical consensus of some of the top diabetes clinicians in the world, and the results are sent in a TIGAR™ Report through our partners to the ordering physician.

As diabetes continues to increase globally, there is a growing need to detect high-risk patients earlier, and classify treated patients more accurately. Through treatment guidance tailored to each individual’s circumstances and pathway function, our goals are to assist the prevention of full onset of the disease with early intervention. This includes healthy eating, increased physical activity, and the selection of the appropriate drug therapy for the individual patient. A proactive management of the patient decreases the rate of deterioration in overall health. There are currently about 422 million diabetics in the world, and this number is expected to grow to 700 million, by 20254.

IR2Dx’s initial product, TIGAR™, is an analytical report focused on measurements of underlying pathway function, using analysis of multi-marker panel tests. The biomarkers used in the IR2Dx analytical reports are interpreted as a pattern to provide a more accurate assessment of a diabetes patient’s current condition, and help lead to optimum management strategies. The TIGAR™ support tools using the marker pattern can be used to select, initially assess response to, and monitor the effects of personalized treatment regimens.

IR2Dx TIGAR™ may be used for any glucose lowering drug therapy, at any stage of disease or loss of metabolic control. The product is particularly valuable in monitoring patients on combination therapies.

The TIGAR™ analytical report incorporates the assessment of seven biomarkers, including high-sensitivity C-reactive protein (hsCRP), intact proinsulin, insulin, adiponectin, C-peptide, Hemoglobin A1c, and estimated GFR (Glomerular Filtration Rate). The specific pattern of the biomarker results by the TIGAR™ analysis, for an individual patient, is the key to a deeper, more informative picture of the patient’s metabolic abnormality. By measuring baseline levels, and subsequent follow-up levels, a physician is able to discern the current state of a patient’s metabolic pathways. This will determine if they are at risk to progress toward more severe disease, and whether or not the patient is receiving optimal treatment, and if needed take appropriate therapeutic action.

To see how our clinical decision support may be used clinically, see our Patient Examples section.